Skip to main content

Table 3 Correlation analysis of LDL size with lipid profile, modified LDLs, HDL composition and Lp-PLA2 activity in patients with type 2 diabetes and control subjects

From: Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes

  DM2 patients Control subjects
  R P R P
HbA1c −0.160 0.071 −0.103 0.601
Insulin −0.076 0.418 0.008 0.937
Total cholesterol −0.185 0.035 −0.326 0.016
Triglycerides −0.553 < 0.001 −0.427 0.001
VLDLc −0.513 < 0.001 −0.423 0.001
LDLc −0.152 0.083 −0.333 0.014
HDLc 0.407 < 0.001 0.096 0.491
NEFA −0.226 0.004 −0.042 0.765
apoB −0.246 0.005 −0.458 < 0.001
apoA-I 0.264 0.002 −0.033 0.811
apoA-II −0.068 0.472 −0.099 0.476
Oxidized LDL −0.390 < 0.001 −0.472 < 0.001
Glycated LDL −0.273 0.003 −0.151 0.307
LDL(-) −0.020 0.828 0.030 0.849
Cholesterol in HDL 0.321 0.002 0.208 0.244
Trigycerides in HDL −0.398 < 0.001 −0.150 0.405
Phospholipids in HDL 0.437 < 0.001 0.067 0.712
apoA-I in HDL −0.205 0.047 0.086 0.635
apoA-II in HDL −0.169 0.103 −0.069 0.739
NEFA in HDL −0.010 0.925 0.086 0.635
PON1 0.016 0.867 0.024 0.872
Total Lp-PLA2 activity −0.123 0.172 0.025 0.862
HDL-Lp-PLA2 activity 0.030 0.745 0.061 0.680
% of HDL-Lp-PLA2 0.191 0.034 0.064 0.662
  1. Bold type indicates the loss of statistical significance in the control group compared to diabetic patients.